The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence

Article Urology & Nephrology

Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups

Matthew J. Roberts et al.

Summary: In patients with post-RP BCR, PSMA-PET findings and receipt of SRT predict event-free survival (EFS). Among patients receiving SRT, PSMA status combined with EAU risk grouping is the most predictive of EFS.

BJU INTERNATIONAL (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Event-free survival after 68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy

Francesco Ceci et al.

Summary: This study aimed to evaluate the incidence of clinically relevant events during follow-up in BCR prostate cancer patients who underwent PSMA-PET. The results showed that high PSA level and short PSAdt were predictors of higher event rates. PSMA-PET can predict the occurrence of clinically relevant events, and patients with negative PSMA-PET have a lower event rate.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Add to Collection

Article Oncology

Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer

Dennie Meijer et al.

Summary: This study compared the oncological outcomes of patients who underwent PSMA-PET imaging before salvage radiation therapy (SRT) with those who did not. The study found that PSMA-PET/CT was associated with improved short-term oncological outcomes in patients with biochemical recurrence.

EUROPEAN UROLOGY ONCOLOGY (2022)

Add to Collection

Article Oncology

Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial

Tobias Hoelscher et al.

Summary: This study suggests that local ablative radiotherapy (aRT) is safe and effective for patients with oligometastatic prostate cancer, and one in five patients had no recurrent prostate-specific antigen after 3 years. This may be an option to avoid systemic therapy in selected patients.

EUROPEAN UROLOGY ONCOLOGY (2022)

Add to Collection

Editorial Material Urology & Nephrology

Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron E-mission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome

Jeremie Calais et al.

EUROPEAN UROLOGY FOCUS (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Francesco Ceci et al.

Summary: The development of consensus guidelines for interpretation of PSMA-PET aims to provide consistent clinical reports, increase data reproducibility in clinical trials, and assist clinicians in making treatment decisions. An expert panel actively participated in a modified Delphi consensus process to implement structured reporting for PSMA-PET. The E-PSMA standardized reporting guidelines supported by the European Association of Nuclear Medicine offer consensus statements among experts in PSMA-PET imaging to harmonize diagnostic interpretation criteria.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

Add to Collection

Review Urology & Nephrology

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Nicolas Mottet et al.

Summary: The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on screening, diagnosis, and treatment of localized prostate cancer summarize the most recent recommendations for clinical practice, including risk-adapted strategies, medical imaging utilization, biopsy techniques, patient classification, and treatment options. Recommendations include consideration of moderate hypofractionation for intermediate-risk patients and a combination of local treatment with long-term hormonal therapy for cN1 PCa patients.

EUROPEAN UROLOGY (2021)

Add to Collection

Review Urology & Nephrology

Salvage therapy for prostate cancer after radical prostatectomy

Nicholas G. Zaorsky et al.

Summary: Biochemical recurrence after radical prostatectomy is common in intermediate-risk and high-risk prostate cancer patients. The optimal management includes a comprehensive evaluation with novel techniques like PET imaging and genomic analysis, along with consideration of traditional clinical variables. Salvage radiotherapy is the only known curative intervention for these patients without metastatic disease, but the importance of accurate timing, radiation dose, and systemic therapy must be emphasized.

NATURE REVIEWS UROLOGY (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging